Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S (GMXAY)

Genmab A/S (GMXAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S

Description:

Genmab A/S, incorporated on June 11, 1998, is a biotechnology company that utilizes antibody products. The Company's first marketed antibody, ofatumumab (Arzerra), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed under a co-development and collaboration agreement with GlaxoSmithKline and has been launched in over two dozen countries. In addition to ofatumumab, it is building a pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need. Its product pipeline includes four antibodies in clinical development and over ten active pre-clinical programs.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 4.86%
3-Year Return 8.23%
5-Year Return 361.29%

Per-Share Information:

Next Earnings Date N/A
Dividend Payout Ratio 0.00%

GMXAY Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow 207.45
Price/Book 12.90
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar